Should I buy or sell Ekso Bionics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares. View EKSO analyst ratings or view top-rated stocks .

What is Ekso Bionics' stock price target for 2024?

1 analysts have issued 1-year price objectives for Ekso Bionics' stock. Their EKSO share price targets range from $9.25 to $9.25. On average, they anticipate the company's share price to reach $9.25 in the next twelve months. This suggests a possible upside of 664.5% from the stock's current price. View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts .

How have EKSO shares performed in 2024?

Ekso Bionics' stock was trading at $2.50 at the beginning of the year. Since then, EKSO stock has decreased by 51.6% and is now trading at $1.21. View the best growth stocks for 2024 here .

Are investors shorting Ekso Bionics?

Ekso Bionics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 134,300 shares, an increase of 20.8% from the March 15th total of 111,200 shares. Based on an average daily volume of 187,700 shares, the short-interest ratio is currently 0.7 days. View Ekso Bionics' Short Interest .

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our EKSO earnings forecast .

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its quarterly earnings results on Monday, March, 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.11. The firm had revenue of $4.85 million for the quarter, compared to analyst estimates of $4.80 million. Ekso Bionics had a negative net margin of 83.14% and a negative trailing twelve-month return on equity of 90.80%. During the same quarter in the prior year, the company posted ($0.24) earnings per share.

When did Ekso Bionics' stock split?

Ekso Bionics shares reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Ekso Bionics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI) , Gran Tierra Energy (GTE) , KushCo (KSHB) , CNBX Pharmaceuticals (CNBX) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Bionano Genomics (BNGO) , Novan (NOVN) , Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA) .

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EKSO

Ekso Bionics (EKSO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free EKSO Stock Alerts

$1.21

-0.07 (-5.47%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.15
▼
$1.29
50-Day Range: $1.26
▼
$2.19
52-Week Range: $0.62
▼
$3.13

Volume: 179,413 shs
Average Volume: 193,836 shs
Market Capitalization: $21.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.25

Get Ekso Bionics alerts:

Ekso Bionics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 664.5% Upside
$9.25 Price Target
Short Interest: Healthy
0.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.48
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.49) to ($0.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

696th out of 918 stocks

General Industrial Machinery, Industry

6th out of 8 stocks

3.5

Analyst's Opinion

Consensus Rating
Ekso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ekso Bionics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.75% of the outstanding shares of Ekso Bionics have been sold short.
Short Interest Ratio / Days to Cover
Ekso Bionics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ekso Bionics has recently increased by 20.77%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ekso Bionics does not currently pay a dividend.
Dividend Growth
Ekso Bionics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EKSO.

1.9

News and Social Media Coverage

News Sentiment
Ekso Bionics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Ekso Bionics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for EKSO on MarketBeat in the last 30 days. This is a decrease of -98% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Ekso Bionics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ekso Bionics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Ekso Bionics is held by insiders.
Percentage Held by Institutions
Only 6.42% of the stock of Ekso Bionics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ekso Bionics are expected to grow in the coming year, from ($0.49) to ($0.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ekso Bionics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ekso Bionics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ekso Bionics has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Ekso Bionics Stock (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.

EKSO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EKSO Stock News Headlines

April 16, 2024 | americanbankingnews.com

Ekso Bionics (NASDAQ:EKSO) Stock Crosses Below 50-Day Moving Average of $1.65

April 13, 2024 | investing.com

Ekso Bionics secures Medicare reimbursement for exoskeleton

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 12, 2024 | globenewswire.com

Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal

April 4, 2024 | morningstar.com

Ekso Bionics Holdings Inc

March 19, 2024 | finanznachrichten.de

Medical Robots Market Worth $33.8 billion | MarketsandMarkets

March 16, 2024 | uk.investing.com

Ekso Bionics director Lathan Corinna buys shares worth $15.5k

March 11, 2024 | finance.yahoo.com

Global Exoskeleton Research Report 2023: From Concept to Reality - Advancements and Challenges in Exoskeleton Developments with Forecasts to 2035

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 6, 2024 | marketwatch.com

Ekso Bionics Shares Fall on Delayed CMS Payment Determination

March 6, 2024 | finance.yahoo.com

Ekso Bionics Holdings Full Year 2023 Earnings: EPS Misses Expectations

March 5, 2024 | finanznachrichten.de

Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Record Annual Revenue of $18.3 Million

March 5, 2024 | seekingalpha.com

Ekso Bionics Holdings, Inc. (EKSO) Q4 2023 Earnings Call Transcript

March 5, 2024 | finance.yahoo.com

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2023 Earnings Call Transcript

March 4, 2024 | investorplace.com

EKSO Stock Earnings: Ekso Bionics Holdings Misses EPS, Beats Revenue for Q4 2023

March 4, 2024 | benzinga.com

Recap: Ekso Bionics Holdings Q4 Earnings

March 4, 2024 | globenewswire.com

Ekso Bionics Reports Record Annual Revenue of $18.3 Million

March 3, 2024 | msn.com

Ekso Bionics Holdings Q4 Earnings Preview

March 3, 2024 | markets.businessinsider.com

Ekso Bionics earnings preview: what to expect

February 26, 2024 | finance.yahoo.com

Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

February 24, 2024 | msn.com

Ekso Bionics Holdings (EKSO) Price Target Increased by 11.11% to 10.20

February 21, 2024 | wsj.com

Ekso Bionics Holdings Inc.

February 6, 2024 | msn.com

Here's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock Now

January 25, 2024 | benzinga.com

(EKSO) - Analyzing Ekso Bionics Holdings's Short Interest

January 23, 2024 | investing.com

Ekso Bionics Holdings Inc (EKSO)

January 23, 2024 | finance.yahoo.com

When Will Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Become Profitable?

January 11, 2024 | marketwatch.com

Ekso Bionics Shares Down After Announcing Stock Offering

See More Headlines

Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/18/2024
Next Earnings (Estimated): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: General industrial machinery,
Sub-Industry: N/A
Current Symbol: NASDAQ:EKSO
Previous Symbol: OTCMKTS:EKSOD
CUSIP: N/A
CIK: 1549084
Web: www.eksobionics.com
Phone: (510) 984-1761
Fax: 510-927-2647
Employees: 70
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.25
High Stock Price Target: $9.25
Low Stock Price Target: $9.25
Potential Upside/Downside: +622.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,200,000.00
Net Margins: -83.14%
Pretax Margin: -83.14%
Return on Equity: -90.80%
Return on Assets: -46.34%

Debt

Debt-to-Equity Ratio: 0.38
Current Ratio: 2.49
Quick Ratio: 1.87

Sales & Book Value

Annual Sales: $18.28 million
Price / Sales: 1.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.85 per share
Price / Book: 1.51

Miscellaneous

Outstanding Shares: 17,900,000
Free Float: 16,560,000
Market Cap: $22.91 million
Optionable: Optionable
Beta: 1.61

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Scott G. Davis (Age 54)
CEO & Director
Comp: $535.8k
Mr. Jerome Wong (Age 50)
Corporate Controller, Corporate Secretary & CFO
Comp: $356.81k
Mr. Jason C. Jones
Chief Operating Officer
Ms. Rachael Anderson
Global Director of Marketing & Strategic Growth
Mr. Anthony Pratt
Vice President of Sales
Ms. Ann Cookson
Human Resources Director
Ms. Foon Lim Chwee
President of APAC
Mr. Stephan Aderhold
Senior VP & GM of EMEA

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EKSO Stock Analysis - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings or view top-rated stocks.
What is Ekso Bionics' stock price target for 2024?: 1 analysts have issued 1-year price objectives for Ekso Bionics' stock. Their EKSO share price targets range from $9.25 to $9.25. On average, they anticipate the company's share price to reach $9.25 in the next twelve months. This suggests a possible upside of 664.5% from the stock's current price.
View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts.
How have EKSO shares performed in 2024?: Ekso Bionics' stock was trading at $2.50 at the beginning of the year. Since then, EKSO stock has decreased by 51.6% and is now trading at $1.21.
View the best growth stocks for 2024 here.
Are investors shorting Ekso Bionics?: Ekso Bionics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 134,300 shares, an increase of 20.8% from the March 15th total of 111,200 shares. Based on an average daily volume of 187,700 shares, the short-interest ratio is currently 0.7 days.
View Ekso Bionics' Short Interest.
When is Ekso Bionics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our EKSO earnings forecast.

How were Ekso Bionics' earnings last quarter?: Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its quarterly earnings results on Monday, March, 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.11. The firm had revenue of $4.85 million for the quarter, compared to analyst estimates of $4.80 million. Ekso Bionics had a negative net margin of 83.14% and a negative trailing twelve-month return on equity of 90.80%. During the same quarter in the prior year, the company posted ($0.24) earnings per share.
When did Ekso Bionics' stock split?: Ekso Bionics shares reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of Ekso Bionics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA).
How do I buy shares of Ekso Bionics?: Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EKSO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial